Oncology
Refine Search
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Japanese biotech PeptiDream edged up 3% to 2,081 yen today, after it announced an expansion of its peptide discovery collaboration with Swiss pharma giant Novartis. 1 May 2024
Biotechnology
UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, has appointed Ashley Nagle as chief business officer (CBO) with immediate effect as part of a broader company expansion. 1 May 2024
Pharmaceutical
US pharma major Eli Lilly today announced its financial results for the first quarter of 2024 and raised it guidance, with the news pushing the firm’s share up 5.6% to $778.19. 30 April 2024
Biotechnology
On April 29, the US Food and Drug Administration granted traditional approval to Tivdak (tisotumab vedotin-tftv) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. 30 April 2024
Biotechnology
Positive data for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate (ADC), have been revealed from the Phase III DESTINY-Breast06 study. 29 April 2024
Pharmaceutical
Osaka, Japan-based drugmaker Ono Pharmaceutical has entered into a drug discovery collaboration agreement with fellow Japanese firm PRISM BioLab. 29 April 2024
Biosimilars
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its April 2024 meeting, as well as two biosimilars. 27 April 2024
Pharmaceutical
US pharma major AbbVie announced financial results for the first quarter of 2024, showing that worldwide net revenues were $12.310 billion, an increase of 0.7% on a reported basis, or 1.6% on an operational basis. 26 April 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
US biotech Gilead Sciences has announced its first-quarter 2024 financial results. 26 April 2024
Pharmaceutical
US pharma giant Merck & Co raised and narrowed its forecasts for profit and sales for 2024 in presenting its first-quarter financial results. 25 April 2024
Pharmaceutical
In its first quarter 2024 results statement, Bristol Myers Squibb beat expectations on revenues, which increased 5% to $11.9 billion, although it posted a loss per share of $5.89, due to charges from recently-closed deals. 25 April 2024
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published its Final Draft Guidance (FDG) on a combination therapy from Swiss pharma giant Novartis. 25 April 2024
Biotechnology
San Diego, USA-based Endeavor BioMedicines has announced the closing of a $132.5 million Series C financing. 25 April 2024
Pharmaceutical
Sanofi shares were up by nearly 4% during Thursday’s early afternoon trading in Paris following its results presentation.. 25 April 2024
Biotechnology
Shares in Britain’s largest drugmaker, AstraZeneca, have surged to a multi-month high following better-than-expected financial results for the first quarter. 25 April 2024
Biotechnology
Cambridge, USA-based biotech Flare Therapeutics (FlareTx) has appointed Douglas Manion as chief executive, effective immediately. 24 April 2024
Pharmaceutical
Swiss pharma giant Roche first-quarter 2024 sales figures this morning that were disappointing in some respects and saw the firm’s shares fall 3.5% to 221.70 francs. 24 April 2024
Biotechnology
Biogen presented its first-quarter 2024 financial results on Wednesday. 24 April 2024
Biotechnology
Day One Biopharmaceuticals closed Tuesday’s trading 8% higher on positive regulatory news. 24 April 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze